Clinical Trials
28 trialsNCT05891171 2026-06-05
ARC-25
Arcus Biosciences, Inc.
Phase 1 Active not recruiting
NCT06257264 2026-06-05
A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors
BeOne Medicines
Phase 1 Active not recruiting
NCT07630961 2026-06-05
Phase I Study of JFI447 [68Ga]Ga-DFC413 and Comparison to FFG233 [68Ga]Ga-NNS309 in Patients With Solid Tumors
Novartis
Phase 1 Not yet recruiting
NCT04300556 2026-06-04
A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types
Eisai Inc.
Phase 1/2 Recruiting
NCT04895709 2026-06-04
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors
Bristol-Myers Squibb
Phase 1/2 Recruiting
NCT05579366 2026-06-03
RAINFOL-01
Genmab
Phase 1/2 Recruiting
NCT07038369 2026-06-03
A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K Mutations
Atavistik Bio, Inc
Phase 1 Active not recruiting
NCT07311993 2026-06-03
Phase 1 Study of CLR 125 in Triple Negative Breast Cancer
Cellectar Biosciences, Inc.
Phase 1 Recruiting
NCT07623369 2026-06-03
A First-in-Human Study of HH160 in Patients With Advanced Solid Tumors
Huahui Health
Phase 1 Not yet recruiting
NCT07623642 2026-06-03
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
GV20 Therapeutics
Phase 2 Not yet recruiting
NCT04981119 2026-06-02
BASECAMP-1
A2 Biotherapeutics Inc.
Recruiting
NCT07046923 2026-06-02
A Study of LY4175408 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Recruiting
NCT05783622 2026-06-01
Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies
Janux Therapeutics
Phase 1 Active not recruiting
NCT06171789 2026-06-01
PRO1107 in Patients With Advanced Solid Tumors
Genmab
Phase 1/2 Terminated
NCT06966700 2026-06-01
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT03289962 2026-05-29
A Study of Autogene Cevumeran (RO7198457) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors
Genentech, Inc.
Phase 1 Completed
NCT06393374 2026-05-29
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06841354 2026-05-29
TroFuse-011
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06926868 2026-05-29
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Bristol-Myers Squibb
Phase 2/3 Recruiting
NCT05181462 2026-05-27
TRIFOUR
Cantargia AB
Phase 1/2 Completed
NCT06657222 2026-05-27
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Tubulis GmbH
Phase 1/2 Recruiting
NCT06533059 2026-05-26
A Study to Learn About Study Medicine ALTA2618 in Adults With AKT1 E17K-Mutant Solid Tumors
Alterome Therapeutics, Inc.
Phase 1 Active not recruiting
NCT06631092 2026-05-26
Personalised Neoantigen-targeting Cancer Vaccine NECVAX-NEO1 in Neoadjuvant Triple-negative Breast Cancer
NEC Bio B.V
Phase 1/2 Recruiting
NCT06238479 2026-05-22
EXCEED
Eli Lilly and Company
Phase 1 Active not recruiting
NCT06465069 2026-05-22
NEXUS-01
Eli Lilly and Company
Phase 1 Recruiting
NCT05537740 2026-05-20
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Bayer
Phase 1 Active not recruiting
NCT06885424 2026-05-20
DESCENT-1
A2 Biotherapeutics Inc.
Enrolling by invitation
NCT07029399 2026-05-19
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
NiKang Therapeutics, Inc.
Phase 1 Recruiting